Signals
84Thyroid cancer targeted therapy expands across differentiated, medullary, and anaplastic subtypes
RET inhibitor maturity, NTRK fusion-targeted use, BRAF V600E and MEK combinations in anaplastic disease, and emerging mechanism programs are restructuring thyroid cancer therapy.
AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
Neurotrophic keratitis acquires recombinant nerve growth factor therapy
Cenegermin (recombinant nerve growth factor) maturity, follow-on programs, and structured corneal-care pathways are reshaping neurotrophic keratitis management.
Hyperemesis gravidarum therapy options widen past doxylamine-pyridoxine
Doxylamine-pyridoxine and ondansetron maturity, structured outpatient infusion pathways, and emerging GDF15-targeted programs are reshaping hyperemesis gravidarum management.
Allergic bronchopulmonary aspergillosis management widens past corticosteroids and itraconazole
Biologic therapy in ABPA, novel azole maturity, and structured diagnostic-and-monitoring pathways are reshaping allergic bronchopulmonary aspergillosis management.
IgG4-related disease enters real prescribing territory
Inebilizumab IgG4-RD pivotal data, rituximab maintenance protocols, and structured diagnostic pathways are reshaping IgG4-related disease management.
Frontotemporal dementia therapy programs reach late-stage trials
Progranulin-replacement therapy in GRN-mutation FTD, ASO programs in C9orf72 FTD-ALS, and tau-targeted programs are emerging in a previously bare category.
Systemic sclerosis therapy options mature past hematopoietic stem cell transplant
Tocilizumab and nintedanib in SSc-ILD, anifrolumab pivotal data, and emerging mechanism-targeted programs are reshaping systemic sclerosis management.
Osteogenesis imperfecta therapy reshapes around anti-sclerostin programs
Setrusumab pivotal data, bisphosphonate maturity, and emerging gene therapy programs are reshaping osteogenesis imperfecta management.
Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Achondroplasia therapy options widen past vosoritide
Vosoritide commercial maturity and follow-on CNP analogue and FGFR3-targeted programs are restructuring achondroplasia management.
CIDP therapy reshapes around FcRn antagonist class entry
Efgartigimod CIDP indication, follow-on FcRn antagonist programs, and structured maintenance protocols are reshaping chronic inflammatory demyelinating polyneuropathy management.
Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Severe COPD biologic therapy class emerges past the inhaler era
Dupilumab COPD approval in eosinophilic phenotype, mepolizumab and benralizumab COPD pivotal data, and ensifentrine entry are reshaping severe COPD management.
Congenital adrenal hyperplasia therapy reshapes around CRF1 receptor antagonism
Crinecerfont approval, follow-on CRF1 receptor antagonist programs, and structured care infrastructure are reshaping classic congenital adrenal hyperplasia management.
Autism spectrum disorder pharmacotherapy options widen past irritability indications
Risperidone and aripiprazole maturity for ASD-associated irritability, emerging mechanism-targeted programs for core symptoms, and integrated multidisciplinary care models are reshaping ASD pharmacotherapy.
Soft tissue sarcoma therapy widens around fusion-defined biomarkers
NTRK inhibitor cross-tumour use, GIST line-of-therapy expansion, and emerging mechanism-targeted programs are reshaping soft tissue sarcoma management.
Cholangiocarcinoma targeted therapy widens past chemotherapy
FGFR2 inhibitor maturity, IDH1 inhibitor use, HER2-targeted therapy entry, and IO combinations are restructuring biliary tract cancer management.
Giant cell arteritis therapy options widen past corticosteroids
Tocilizumab maturity, secukinumab pivotal data, and emerging mechanism-targeted programs are reshaping giant cell arteritis management.
Phenylketonuria therapy options mature past low-phenylalanine diet
Pegvaliase commercial maturity, sapropterin use, and emerging gene therapy programs are restructuring phenylketonuria management.
Genitourinary syndrome of menopause therapy widens past systemic hormone therapy
Vaginal estrogen formulation maturity, ospemifene and prasterone uptake, and emerging non-hormonal mechanism programs are restructuring genitourinary syndrome of menopause management.
Lipid management therapy widens past statins and PCSK9 monoclonals
Inclisiran maturity, bempedoic acid, lepodisiran and emerging oral PCSK9 programs, and ANGPTL3-targeted therapy are restructuring lipid management.
ANCA-associated vasculitis therapy options mature around avacopan
Avacopan commercial maturity, rituximab maintenance protocols, and emerging mechanism programs are restructuring ANCA-associated vasculitis management.
Chronic neuropathic pain therapy reshapes around novel sodium channel mechanisms
Suzetrigine (Nav1.8 inhibitor) acute pain approval and follow-on Nav1.8 and Nav1.7 programs in chronic pain are reshaping non-opioid pain management.
Chronic rhinosinusitis with nasal polyps biologic class matures
Dupilumab maturity, mepolizumab and benralizumab CRSwNP indications, omalizumab CRSwNP approval, and emerging mechanism programs are reshaping CRSwNP management.
Allergic conjunctivitis therapy widens past topical antihistamines
Topical multi-action options, novel mechanism programs, and emerging biologic-pathway therapy are reshaping allergic conjunctivitis management.
Cannabis use disorder pharmacotherapy programs reach late-stage trials
Late-stage cannabis use disorder pharmacotherapy programs and integrated behavioural-and-pharmacological care models are emerging in a previously bare category.
Alopecia areata therapy class competition matures
Baricitinib, ritlecitinib, and deuruxolitinib establish a competitive systemic JAK inhibitor class in severe alopecia areata.
Glioblastoma therapy options evolve past temozolomide and TTFields
Tumour-treating fields maturity, IDH-mutant glioma vorasidenib approval, and emerging mechanism-targeted programs are reshaping glioma management.
Neuromyelitis optica spectrum disorder therapy class competition matures
Eculizumab, ravulizumab, satralizumab, inebilizumab, and emerging mechanism programs define a competitive NMOSD prescribing landscape.
Vasomotor symptom therapy expands past fezolinetant
Elinzanetant approval, follow-on NK3 receptor antagonist programs, and combination NK1-NK3 approaches are restructuring vasomotor symptom management.
Presbyopia pharmacological options widen past pilocarpine
Pilocarpine maturity, follow-on miotic-class programs, and emerging non-miotic mechanism programs are reshaping presbyopia management.
Chimeric autoantibody receptor T cells enter pemphigus vulgaris
Desmoglein 3-targeted CAART cell therapy programs in pemphigus vulgaris are reading out as a precision approach to autoantibody-driven disease.
Restless legs syndrome therapy reshapes around augmentation avoidance
Alpha-2-delta ligand first-line preference, low-dose opioid use, and novel mechanism programs are restructuring restless legs syndrome management.
Post-stroke spasticity therapy options widen past oral baclofen
Botulinum toxin maturity, intrathecal baclofen pump access, and emerging novel mechanism programs are reshaping post-stroke spasticity management.
Colorectal cancer third-line and KRAS-targeted options widen
KRAS G12C-targeted programs, fruquintinib third-line use, and trastuzumab deruxtecan in HER2-amplified colorectal are restructuring late-line colorectal cancer.
Tobacco use disorder pharmacotherapy widens past nicotine replacement and varenicline
Cytisine availability, novel nicotine receptor pharmacotherapy, and integrated behavioural-and-pharmacological care delivery are reshaping tobacco use disorder management.
Heart failure with reduced ejection fraction therapy moves beyond four-pillar standard
Vericiguat addition, mechanism-targeted programs, and emerging genetically-defined HFrEF approaches are reshaping the post-four-pillar landscape.
Obstructive sleep apnea pharmacotherapy emerges past CPAP-and-MAD
Tirzepatide OSA approval, follow-on GLP-1 OSA programs, and upper airway pharmacological programs are reshaping obstructive sleep apnea management.
Pediatric severe asthma biologic options expand
Dupilumab, mepolizumab, benralizumab, and tezepelumab paediatric label expansions plus emerging biologic programs are restructuring paediatric severe asthma.
Lupus nephritis therapy options mature past induction-and-maintenance
Voclosporin and belimumab in lupus nephritis plus emerging mechanism programs are restructuring induction and maintenance therapy.
Chronic kidney disease therapy options widen in non-diabetic populations
Finerenone in non-diabetic CKD, SGLT2 expansion past diabetes, and novel mechanism programs are restructuring CKD management beyond the diabetic kidney disease frame.
Keratoconus therapy widens past corneal cross-linking
Corneal cross-linking adoption, intracorneal ring segment maturity, and emerging custom cross-linking and topography-guided treatment are reshaping keratoconus management.
Refractory chronic cough acquires a first targeted mechanism class
P2X3 antagonist class entry plus follow-on novel mechanism programs are establishing chronic cough as a real prescribing category.
Stroke prevention restructures across atrial fibrillation, lipids, and acute window
Factor XIa inhibitors entering late-stage trials, expanded thrombectomy windows, and tenecteplase displacement of alteplase are restructuring stroke prevention and acute care.
Type 1 diabetes therapy reshapes around disease modification and automation
Teplizumab disease modification, automated insulin delivery system maturity, and emerging beta-cell replacement programs are restructuring T1D management.
Postmenopausal osteoporosis therapy reshapes around anabolic-first sequencing
Romosozumab maturity, ongoing teriparatide and abaloparatide use, and follow-on anabolic programs are restructuring postmenopausal osteoporosis sequencing.
Gastric and gastroesophageal cancer therapy reshapes around HER2 maturity and claudin18.2 entry
Trastuzumab deruxtecan in HER2-low gastric, claudin18.2-targeted zolbetuximab approval, and IO combinations are restructuring upper GI oncology.
Dementia behavioural symptoms acquire approved pharmacotherapy
Brexpiprazole approval for agitation in Alzheimer's dementia and follow-on programs are reshaping dementia behavioural symptom management.
Thyroid eye disease therapy grows past teprotumumab
Teprotumumab maturity plus follow-on IGF-1R-targeted programs and novel non-IGF-1R mechanism classes are restructuring thyroid eye disease management.
MASH therapy class establishes after resmetirom approval
Resmetirom commercial uptake plus follow-on FGF21 analogues, GLP-1 plus glucagon, and PPAR-pan agonists are establishing a real metabolic-dysfunction-associated steatohepatitis prescribing class.
Hidradenitis suppurativa biologic options widen past TNF
IL-17-class secukinumab and bimekizumab approvals plus emerging novel mechanism programs are restructuring hidradenitis suppurativa management.
Hereditary angioedema oral options reach maturity
Oral plasma kallikrein inhibitors and emerging factor XIIa inhibitor programs are restructuring HAE prophylaxis and on-demand therapy.
Diabetic peripheral neuropathy therapy advances after a long quiet period
Capsaicin patch maturity, novel sodium channel modulators, and emerging disease-modifying programs are reshaping diabetic peripheral neuropathy management.
Sjogren disease therapy enters real prescribing territory
First positive pivotal readouts in Sjogren disease are establishing a category that has had no specific systemic therapy for decades.
Inherited retinal disease gene therapy widens past RPE65
X-linked retinitis pigmentosa, choroideremia, and additional inherited retinal disease gene therapy programs are reading out.
Hepatocellular carcinoma systemic therapy options mature
Atezolizumab plus bevacizumab maturity, durvalumab plus tremelimumab adoption, and TIGIT-class programs are restructuring advanced HCC.
Sarcoidosis acquires mechanism-targeted therapy after a long quiet period
Efzofitimod late-stage data and other emerging mechanism-targeted programs are reshaping pulmonary sarcoidosis after years of corticosteroid-only first-line.
Obsessive-compulsive disorder modern options mature
Deep brain stimulation maturity, novel glutamate-modulator programs, and refined transcranial magnetic stimulation protocols are reshaping refractory OCD management.
Genetically-targeted Parkinson's programs reach pivotal data
LRRK2 inhibitors and GBA-targeted programs in Parkinson's disease are reading out as the first genetically-defined Parkinson's therapy options.
OCD and intractable-condition options widen
Deep brain stimulation, transcranial magnetic stimulation, and emerging psychedelic-assisted therapy are all reaching into refractory OCD.
Tumor-infiltrating lymphocyte therapy expands past melanoma
TIL therapy approval in metastatic melanoma is opening pathways into cervical and other solid tumour indications.
Fertility therapy moves from procedural to pharmacological
Pharmacological adjuncts and oocyte-quality interventions are expanding the fertility-therapy toolset beyond the IVF procedural footprint.
Cell therapy moves into non-malignant rare disease
Cell-therapy approaches are beginning to land in non-malignant rare-disease indications including severe lupus, scleroderma, and inherited metabolic conditions.
Choroidal melanoma therapy options widen
Approved tebentafusp and emerging programs are creating the first systemic therapy options for metastatic choroidal melanoma.
Non-CF bronchiectasis enters the therapy frontier
Late-stage programs targeting non-CF bronchiectasis are creating the first specific therapy category for this long-overlooked condition.
Apolipoprotein C3-targeted therapy expands lipid management
ApoC3-targeted programs are widening the triglyceride-lowering toolset and entering routine lipid practice.
FDA approves tividenofusp alfa for neurologic Hunter syndrome
The FDA approved Avlayah (tividenofusp alfa-eknm) to treat the neurologic manifestations of MPS II (Hunter syndrome), marking the first therapy specifically indicated for the CNS dimension of this rare lysosomal storage disorder.
Bispecific T-cell engager uptake in lymphoma is constrained by cytokine-release-syndrome management capacity
Bispecific T-cell engagers in B-cell lymphoma are demonstrating strong response rates in late-line settings, but commercial uptake is limited by the cytokine-release-syndrome management infrastructure required for safe administration. The constraint is more binding than the clinical evidence base suggests.
ASO platform diversification beyond DMD is reshaping rare-disease commercial planning
The antisense oligonucleotide (ASO) platform has moved beyond the DMD foundation into multiple rare-disease indications including SMA, AdLD, Stargardt disease and adjacent conditions. The platform-level commercial logic is reshaping rare-disease portfolio strategy at multiple sponsors.
PROTAC oncology pipeline is transitioning from concept to commercial reality
Targeted protein degradation programs (PROTACs and molecular glues) in oncology have moved from early-stage proof-of-concept to multiple late-stage assets with pivotal readouts in the next 24 months. The mechanism's promise of drugging previously undruggable targets is closer to commercial validation than at any prior point.
IPF antifibrotic class is evolving with second-generation mechanisms
Idiopathic pulmonary fibrosis treatment has been defined by the two approved antifibrotics (pirfenidone, nintedanib) for a decade. The second-generation pipeline is now reading out, with mechanisms targeting different points in the fibrotic pathway and the potential to combine with the established class.
Gantenerumab post-mortem: what the failure tells the field about Abeta-targeting
The gantenerumab phase 3 readout failure is a useful data point for understanding what differentiates the successful anti-amyloid antibody class from the unsuccessful programs. The implications for next-generation amyloid-targeting and adjacent neurodegeneration pipeline are material.
Schizophrenia pipeline shifts from D2 to muscarinic mechanisms
The schizophrenia therapeutic pipeline is shifting from the dopamine D2 receptor mechanism that has defined antipsychotic therapy for fifty years toward muscarinic receptor mechanisms with substantively different efficacy and tolerability profiles. The implications for the schizophrenia commercial category are material.
KRAS G12C resistance patterns are reshaping second-line NSCLC sequencing
Resistance mechanisms emerging from sotorasib and adagrasib post-progression sampling are converging on a finite set of pathways. The implications for second-line decision-making and combination design are starting to land in clinic.
TROP2 ADC class read-throughs from Q1 2026 readouts
The TROP2 antibody-drug conjugate class has multiple late-stage assets reading out in overlapping breast cancer and NSCLC populations. Q1 2026 readouts have started to differentiate the class on toxicity profile and biomarker dependency rather than on bulk efficacy.
Antibody-drug conjugates are reshaping the HER2-low breast cancer setting
T-DXd's expansion into HER2-low has changed second-line decision-making, and the ADC class is delivering further candidates that are likely to redefine biomarker-driven sequencing across breast cancer subtypes.
Psychedelic-assisted therapy: clinical pipeline progress, regulatory caution
MDMA- and psilocybin-based therapies have advanced through late-stage trials, but the FDA's measured response - and the system requirements those therapies impose on delivery - mean rollout will be slower and more constrained than mechanism enthusiasm suggested.
Severe asthma biologics: which patients are still being left out?
Type-2 biologics have transformed severe eosinophilic asthma management, but a meaningful subset of severe-asthma patients - those without high eosinophils, FeNO, or specific allergic phenotypes - still lack a biomarker-aligned biologic option.
Tau PET reimbursement is the next diagnostic access question
Amyloid PET has settled into routine coverage and availability. Tau PET - which will be the confirmatory pathway for tau-directed therapies - is sited at meaningfully fewer centers and reimbursed unevenly. The access conversation that defined anti-amyloid rollout is about to repeat, one mechanism later.
Co-pathology recognition is reshaping how Alzheimer's diagnosis is being read
LATE, vascular contribution, and Lewy-body co-pathology are now routinely on the differential when a patient with cognitive symptoms tests amyloid-positive. The clinical question is increasingly "what mix" rather than "is it Alzheimer's."
GLP-1 receptor agonists enter Alzheimer's clinical trials
Phase 3 readouts on semaglutide in Alzheimer's are due, with mechanistic interest in metabolic, vascular, and inflammatory pathways.
FDA's accelerated approval pathway under continued post-Aduhelm scrutiny
Aducanumab's voluntary withdrawal in 2024 left lasting institutional caution about surrogate-endpoint approvals in neurodegeneration.
Tau-targeting programs advance behind the amyloid wave
Anti-tau immunotherapies and small molecules are progressing through mid-stage trials, with the field watching for the first credible clinical signal.
Snapshots
21Antisense oligonucleotide platform landscape (2026 reference)
Reference snapshot of approved ASO therapies, late-stage programs, and the delivery and chemistry platforms behind them.
Anti-amyloid antibody landscape, 2026 mid-year reference
A dated reference snapshot of the anti-amyloid antibody class for Alzheimer's disease as of mid-2026: approved products, withdrawn products, late-stage pipeline, label-defining clinical evidence, and the operational pattern that defines the class.
Bipolar disorder treatment landscape, 2026 mid-year reference
Reference layout of the bipolar disorder treatment landscape as of mid-2026: mood stabilisers, atypical antipsychotics, antidepressant adjuncts, the depression-versus-mania-versus-maintenance prescribing logic, and the live commercial questions across the pipeline.
COPD pipeline expansion, 2026 mid-year reference
Reference layout of the COPD therapeutic pipeline as of mid-2026: established inhaled bronchodilator and inhaled corticosteroid combinations, the emerging biologic class (anti-IL-5, anti-IL-33, anti-TSLP), novel small-molecule mechanisms, and the live commercial questions across the pipeline.
Rare disease enzyme replacement therapy landscape, 2026 mid-year reference
Reference layout of the enzyme replacement therapy class in rare disease as of mid-2026: approved assets across lysosomal storage disease, the next-generation engineered-enzyme programs, the gene therapy alternatives, and the live commercial questions including chronic-infusion burden and CNS access.
IBD biologic and small-molecule landscape, 2026 mid-year reference
Reference layout of the IBD therapeutic class as of mid-2026: approved biologics (anti-TNF, anti-integrin, IL-12/23, IL-23), oral small molecules (JAK, S1P modulators, TYK2 in pipeline), and the live commercial questions including line-of-therapy positioning and combination strategy.
Bispecific antibody class landscape in oncology, 2026 mid-year reference
Reference layout of the bispecific antibody class in oncology as of mid-2026: approved assets across haematology and solid tumours, the T-cell engager subclass, the dual-checkpoint subclass, and the live commercial questions including site-of-care infrastructure and combination strategy.
Glaucoma treatment landscape, 2026 mid-year reference
Reference layout of the glaucoma treatment landscape as of mid-2026: pressure-lowering eye drop classes, sustained-release drug-delivery implants, microinvasive glaucoma surgery, and the live commercial questions including adherence, procedure-room capacity, and the next-generation pipeline.
ATTR cardiomyopathy treatment landscape, 2026 mid-year reference
Reference layout of the ATTR cardiomyopathy treatment landscape as of mid-2026: TTR stabilisers, TTR silencers, the diagnostic-pathway infrastructure, and the live commercial questions including diagnostic-pathway expansion and combination therapy.
Maternal mental health pipeline, 2026 mid-year reference
Reference layout of the maternal mental health pipeline as of mid-2026: approved mechanisms for postpartum depression, late-stage assets for perinatal mood disorders and adjacent indications, and the live commercial questions including screening pathway and access frame.
Retinal therapy pipeline, 2026 mid-year reference
Reference layout of the retinal therapy pipeline as of mid-2026: approved mechanisms across wet AMD, DME, GA, and inherited retinal dystrophy, late-stage pipeline by mechanism, and the live commercial questions including delivery innovation, biosimilar dynamics, and gene-therapy progress.
Psoriasis biologics landscape, 2026 mid-year reference
Reference layout of the psoriasis biologic class as of mid-2026: approved mechanisms, first-line versus later-line positioning, the IL-23 dominance picture, and the live commercial questions for the class.
Treatment-resistant depression pipeline, 2026 mid-year reference
Reference layout of the treatment-resistant depression pipeline as of mid-2026: approved mechanisms, late-stage assets, the psychedelic and ketamine-class programs, novel non-monoamine mechanisms, and the live commercial questions across the pipeline.
Obesity drug pipeline, 2026 mid-year reference
Reference layout of the obesity drug pipeline as of mid-2026: approved mechanisms, late-stage assets, the dual and triple agonist class, and the live commercial questions including manufacturing capacity, cardiovascular outcomes, and the indication-by-indication coverage frame.
DMD treatment landscape, 2026 mid-year reference
Reference layout of the Duchenne muscular dystrophy treatment landscape as of mid-2026: approved mechanisms across exon-skipping, gene therapy, and corticosteroid-class agents, late-stage pipeline, and the live commercial questions across patient populations.
Endometriosis pipeline, 2026 mid-year reference
Reference layout of the endometriosis pipeline as of mid-2026: approved mechanisms, late-stage assets, the GnRH antagonist class, the non-hormonal pipeline, and the live commercial questions including diagnosis-pathway access and the surgical-medical interplay.
Approved gene therapies by indication, 2026 mid-year reference
Reference layout of approved in vivo and ex vivo gene therapies as of mid-2026: indications, mechanism, delivery vector or platform, regulatory pathway, and the live commercial questions for each.
ADC class landscape, 2026 mid-year reference
Reference layout of the antibody-drug conjugate class in oncology as of mid-2026: approved assets by target and indication, late-stage pipeline by mechanism, and the live differentiation axes the field is settling on.
What we are watching in Alzheimer's, as of Q2 2026
A reference list of the threads PatientSpotlight is actively tracking - clinical readouts, regulatory and reimbursement decisions, real-world evidence accumulation, and operational rollout. Each thread names what to watch and why it matters, without predicting when it will resolve.
Alzheimer's drug development pipeline, as of Q2 2026
A reference view of the late-stage Alzheimer's pipeline as of Q2 2026 - tau-directed programs, GLP-1 receptor agonists, neuroinflammation, synaptic and neuronal resilience, and genetic/protein-clearance approaches.
Disease-modifying therapies in Alzheimer's, as of Q2 2026
Two anti-amyloid antibodies have traditional FDA approval; subcutaneous formulations are advancing; the post-amyloid pipeline is portfolio-shaped.
Explained
5How chronic cough has emerged as a discrete indication with its own pipeline
Chronic cough was historically managed within the broader respiratory and ENT framework as a symptom rather than as an indication. The emergence of P2X3 receptor antagonists and adjacent novel mechanisms has established chronic cough as a discrete therapeutic indication with a distinct pipeline, regulatory pathway and commercial logic.
How inherited retinal dystrophy gene therapy is moving beyond RPE65
The voretigene neparvovec approval for RPE65-mediated inherited retinal dystrophy validated AAV-based gene therapy in ophthalmology. The pipeline has moved substantially beyond RPE65 to address adjacent inherited retinal dystrophy genotypes, with implications for diagnostic infrastructure, surgical delivery, and commercial planning.
Why 'women's health' is being rebuilt from a neglected indication frame to a commercial category
For most of the modern pharmaceutical era, 'women's health' meant contraception and hormone-replacement therapy. The conditions outside that frame - endometriosis, polycystic ovary syndrome, menopause symptoms, female-specific cardiovascular and metabolic conditions - were under-funded relative to disease burden. That is changing structurally, and the commercial implications are larger than any single therapy.
What are GLP-1 receptor agonists, and why are they being tested in Alzheimer's?
GLP-1 receptor agonists are a class of drugs originally developed for type 2 diabetes and now widely used for obesity. The class is now in late-stage Alzheimer's trials. The mechanistic case spans metabolic, vascular, inflammatory, and direct neuronal pathways - and the access shape would be very different from anti-amyloid therapy.
What is the FDA accelerated approval pathway, and why does it matter for Alzheimer's?
Accelerated approval is a 1992 FDA regulatory pathway that lets a drug come to market based on a surrogate endpoint reasonably likely to predict clinical benefit, with a confirmatory trial obligated to follow. In Alzheimer's, the pathway is closely associated with the aducanumab episode and a recalibrated bar for what surrogate evidence the agency now considers persuasive.